SELLAS Life Sciences Group, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $0.00.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $66.00K, a 37.50% increase year-over-year.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $0.00.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $63.00K, a 34.04% increase year-over-year.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $112.00K, a 14.29% increase from fiscal 2024.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $98.00K, a 8.41% decline from fiscal 2023.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $107.00K, a 25.88% increase from fiscal 2022.
- SELLAS Life Sciences Group, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $85.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $129.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $66.00K 10-Q · filed 2026-05-12 | $129.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $112.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $63.00K 10-Q · filed 2025-11-12 | $111.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $95.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $48.00K 10-Q · filed 2026-05-12 | $95.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $98.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $47.00K 10-Q · filed 2025-11-12 | $98.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $105.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $51.00K 10-Q · filed 2025-05-13 | $105.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $107.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $54.00K 10-Q · filed 2024-11-13 | $107.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $91.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $53.00K 10-Q · filed 2024-05-14 | $91.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $85.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $38.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | |
| 2022-03-31 | $47.00K 10-Q · filed 2023-05-11 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $2.56M derived: sum of 4 quarters · filed 2017-11-09 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $2.58M derived: sum of 4 quarters · filed 2017-08-14 |
| 2017-03-31 | $5.00K 10-Q · filed 2017-05-10 | $2.58M derived: sum of 4 quarters · filed 2017-05-10 |
| 2016-12-31 | $2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $2.65M 10-K · filed 2017-03-15 |
| 2016-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $95.00K derived: sum of 4 quarters · filed 2017-03-15 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $277.00K derived: sum of 4 quarters · filed 2017-03-15 |
| 2016-03-31 | $78.00K 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $309.00K 10-K · filed 2017-03-15 |
| 2015-09-30 | $199.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | |
| 2014-12-31 | $153.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $263.00K 10-K · filed 2017-03-15 |
| 2014-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-07 | $204.00K derived: sum of 4 quarters · filed 2016-04-15 |
| 2014-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | |
| 2014-03-31 | $53.00K 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $94.00K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2016-04-15 | $163.00K 10-K/A · filed 2016-04-15 |
| 2012-12-31 | $93.00K 8-K · filed 2015-12-04 | |
| 2011-12-31 | $15.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |